Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-17-8463-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.22 billion
Profitability
Miscellaneous
Employees3,700
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) released its earnings results on Tuesday, November, 5th. The company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The business earned $743.70 million during the quarter, compared to the consensus estimate of $770.56 million. Mallinckrodt had a positive return on equity of 24.36% and a negative net margin of 111.44%. The business's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period last year, the company earned $2.10 earnings per share. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What price target have analysts set for MNK?
14 brokers have issued 12-month price objectives for Mallinckrodt's shares. Their forecasts range from $2.00 to $22.00. On average, they anticipate Mallinckrodt's share price to reach $8.64 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price. View Analyst Price Targets for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.
Has Mallinckrodt been receiving favorable news coverage?
News stories about MNK stock have been trending negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mallinckrodt earned a news impact score of -2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Mallinckrodt.
Are investors shorting Mallinckrodt?
Mallinckrodt saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 46,160,000 shares, a decline of 9.4% from the November 28th total of 50,930,000 shares. Based on an average daily volume of 7,250,000 shares, the short-interest ratio is presently 6.4 days. Approximately 55.7% of the company's shares are short sold. View Mallinckrodt's Current Options Chain.
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Forty Seven (FTSV), Zymeworks (ZYME), Arvinas (ARVN), Tricida (TCDA), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Amneal Pharmaceuticals (AMRX), Esperion Therapeutics (ESPR), Alder Biopharmaceuticals (ALDR), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Intra-Cellular Therapies (ITCI), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA) and Theravance Biopharma (TBPH).
What other stocks do shareholders of Mallinckrodt own?
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
- Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
- Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by many different of institutional and retail investors. Top institutional investors include Clear Creek Financial Management LLC (0.03%), Beirne Wealth Consulting Services LLC (0.03%) and Commerzbank Aktiengesellschaft FI (0.02%). Company insiders that own Mallinckrodt stock include Bryan M Reasons, James E Flynn and Mark Trudeau. View Institutional Ownership Trends for Mallinckrodt.
Which major investors are selling Mallinckrodt stock?
Which major investors are buying Mallinckrodt stock?
MNK stock was purchased by a variety of institutional investors in the last quarter, including Beirne Wealth Consulting Services LLC. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons and Mark Trudeau. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $5.20.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $437.27 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe.View Additional Information About Mallinckrodt.
What is Mallinckrodt's official website?
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
